Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab
- 41 Downloads
The objective of this study was to investigate the effect of renin–angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients.
Materials and methods
We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups. The primary outcome was a proteinuria event of any grade during the first 6 cycles of BV treatment.
A total of 211 patients were included, 89 of whom received antihypertensive drugs. Of these 89 patients, 49 were in the RASI user group, and 40 were in the non-RASI user group. The non-user group comprised 122 patients. The occurrence of proteinuria in the RASI user group was significantly lower than that in the non-RASI user group (P = 0.037) but was not significantly lower than that in the non-user group (P = 0.287). Patients using RASIs had a lower rate of proteinuria than those who did not use RASIs according to multivariate analysis (odds ratio 0.32; 95% confidence interval 0.12–0.86; P = 0.024).
Our study suggests that RASI administration reduces the risk of proteinuria in patients receiving BV.
KeywordsBevacizumab Renin–angiotensin system inhibitor Non-small cell lung cancer Proteinuria
This research study received no specific grant from any funding agency in the public, commercial, or not-for-profit sector. The following principal investigators and institutions contributed to the study: Y. Mori (Iwate Prefectural Central Hospital), H. Yokouchi (Fukushima Medical University Hospital), K. Taima (Hirosaki University Hospital), M. Maemondo (Miyagi Cancer Center), and H. Watanabe (Saka General Hospital).
Compliance with ethical standards
Conflict of interest
The authors have declared no conflicts of interest.
Research involving human participants and/or animals
Formal consent is not required for this type of study.
Informed consent is not required for this type of study.
This study was approved by the institutional review board of each participating institution and was conducted according to institutional and ethical rules concerning research on tissue specimens and patients.
- 2.Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019. https://doi.org/10.1200/JCO.2007.14.9930 CrossRefPubMedGoogle Scholar
- 3.Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345 CrossRefPubMedGoogle Scholar
- 9.Greka A, Mundel P (2012) Cell biology and pathology of podocytes. Annu Rev Physiol 74:299–323. https://doi.org/10.1146/annurev-physiol-020911-153238 CrossRefPubMedGoogle Scholar
- 11.Yu SY, Qi R, Zhao H (2013) Losartan reverses glomerular podocytes injury induced by Ang II via stabilizing the expression of GLUT1. Mol Biol 40:6295–6301Google Scholar
- 13.US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2010 (2014) http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 31 Dec 2014
- 14.Crinò L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou C (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733–740. https://doi.org/10.1016/S1470-2045(10)70151-0 CrossRefPubMedGoogle Scholar
- 15.Yoh K, Hosomi Y, Kasahara K, Yamada K, Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, Enatsu S, Lee P, Ferry D, Tamura T, Nakagawa K (2016) A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99:186–193. https://doi.org/10.1016/j.lungcan.2016.07.019 CrossRefPubMedGoogle Scholar
- 16.Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136. https://doi.org/10.1056/NEJMoa0707330 CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004–3011. https://doi.org/10.1200/JCO.2012.42.3749 CrossRefPubMedGoogle Scholar
- 21.Ramirez SP, McClellan W, Port FK, Hsu SI (2002) Risk factors for proteinuria in a large, multiracial, Southeast Asian population. J Am Soc Nephrol 13:1907–1917. https://doi.org/10.1097/01.ASN.0000018406.20282.C8 CrossRefPubMedGoogle Scholar
- 25.Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG, African American Study of Kidney Disease and Hypertension Study Group (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial Group. JAMA 288:2421–2431CrossRefPubMedGoogle Scholar
- 26.Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860. https://doi.org/10.1056/NEJMoa011303 CrossRefPubMedGoogle Scholar
- 28.Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282–284. https://doi.org/10.1093/jnci/djm311 CrossRefPubMedGoogle Scholar
- 31.Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 28:949–954. https://doi.org/10.1200/JCO.2009.25.4482 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS One 10:e0116527. https://doi.org/10.1371/journal.pone.0116527 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, Molven A, Lønning PE, Akslen LA, Straume O (2012) Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLoS One 7:e38364. https://doi.org/10.1371/journal.pone.0038364 CrossRefPubMedPubMedCentralGoogle Scholar